Navigation Links
Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
Date:12/12/2007

NEW YORK, Dec. 12 /PRNewswire-USNewswire/ -- Having funded $2 million total to support 27 high-risk, high-reward approaches to Parkinson's disease research in the first year of its Rapid Response Innovation Awards (RRIA) initiative, The Michael J. Fox Foundation today announced that it will commit $2 million to a second round of funding in 2008. RRIA is designed to ensure that researchers can pursue good ideas without delay. Under this program the Foundation accepts proposals on a rolling basis with no deadline, makes funding decisions within six weeks of application and speeds up to $75,000 to one-year basic, preclinical or clinical research projects in any Parkinson's-relevant arena.

"RRIA funds 'flashes of insight' in real time, hopefully helping to open new avenues for PD therapy development," said Katie Hood, interim CEO of The Michael J. Fox Foundation.

To accommodate these "flashes of insight," the program's criteria and application process are designed with novelty and speed in mind.

Todd Sherer, PhD, vice president of research programs at MJFF, said: "We set up RRIA to attract new researchers to Parkinson's and to provide support for unorthodox ideas -- the sort that could significantly impact PD treatment, but that may have little or no preliminary data, making it hard or impossible to find traditional funding to carry them out. Based on the strong response from the scientific community in 2007, it's clear this program is filling a need."

The program is designed to provide funding for strong ideas being tested for the first time. Unlike other Foundation initiatives, RRIA allows for the submission of applications at any time of year. There is no pre-proposal stage, and the standard application has been shortened to three pages. Additionally, postdoctoral researchers are permitted to apply as principal investigators under this initiative provided the head of their lab serves as Administrative PI to assist with the provision of institutional documents and sign the award contract.

Projects funded in 2008 include:

-- A project testing whether isradipine, a high-blood-pressure drug

already approved for use in humans, protects dopamine neurons in an

animal model of Parkinson's disease;

-- Development of nanoparticle technology as a non-viral gene therapy

technique that could help overcome the delivery challenges of getting

PD therapeutics past the blood-brain barrier;

-- A project to test the Braak Hypothesis, which posits that sporadic

Parkinson's may begin not in the central nervous system but in the

enteric, or gastrointestinal, nervous system -- knowledge that would

provide revolutionary insights into the pathogenesis and progression

of PD; and

-- Initial work to determine whether low levels of a gene called ST13

predict risk of future PD (which could lead to the development of

a practical, widely available blood test for early and objective

diagnosis of Parkinson's disease).

A complete list of projects funded under RRIA 2007, including researcher bios and grant abstracts, is available at http://www.michaeljfox.org.

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded $100 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. National Patient Safety Foundation Partners with Vocera Communications
11. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 , ... "Add realistic flares ... flicker, flash, and flare from clip to clip with high quality 4K lens flare ... 4K Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing the Dragon ...
(Date:12/5/2016)... , ... December 05, 2016 , ... What: Shriners Hospitals ... the North Pole to our patients – using a video monitor and web-enabled camera. ... hospital will transform the Auditorium into a Christmas Wonderland, which is where the video ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward ... to announce the arrival of the newest Sciton laser in January 2017. The ... use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, ...
(Date:12/5/2016)... ... ... For many years, Andrew G. Zubinas has accumulated over 130 ... the Lithuanian language and its poetry inspired him in writing “ Forest ... all aspects of a living, breathing forest where nothing ever stays the same. His ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted from ... Executive® (ISE®) Central Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology: